Literature DB >> 30728248

Long-Term Engraftment of Human Cardiomyocytes Combined with Biodegradable Microparticles Induces Heart Repair.

Laura Saludas1, Elisa Garbayo1, Manuel Mazo1, Beatriz Pelacho1, Gloria Abizanda1, Olalla Iglesias-Garcia1, Angel Raya1, Felipe Prósper1, María J Blanco-Prieto2.   

Abstract

Cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs) are a promising cell source for cardiac repair after myocardial infarction (MI) because they offer several advantages such as potential to remuscularize infarcted tissue, integration in the host myocardium, and paracrine therapeutic effects. However, cell delivery issues have limited their potential application in clinical practice, showing poor survival and engraftment after transplantation. In this work, we hypothesized that the combination of hiPSC-CMs with microparticles (MPs) could enhance long-term cell survival and retention in the heart and consequently improve cardiac repair. CMs were obtained by differentiation of hiPSCs by small-molecule manipulation of the Wnt pathway and adhered to biomimetic poly(lactic-co-glycolic acid) MPs covered with collagen and poly(d-lysine). The potential of the system to support cell survival was analyzed in vitro, demonstrating a 1.70-fold and 1.99-fold increase in cell survival after 1 and 4 days, respectively. The efficacy of the system was tested in a mouse MI model. Interestingly, 2 months after administration, transplanted hiPSC-CMs could be detected in the peri-infarct area. These cells not only maintained the cardiac phenotype but also showed in vivo maturation and signs of electrical coupling. Importantly, cardiac function was significantly improved, which could be attributed to a paracrine effect of cells. These findings suggest that MPs represent an excellent platform for cell delivery in the field of cardiac repair, which could also be translated into an enhancement of the potential of cell-based therapies in other medical applications.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30728248     DOI: 10.1124/jpet.118.256065

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

Review 1.  Fiber Scaffold Patterning for Mending Hearts: 3D Organization Bringing the Next Step.

Authors:  Marleen Kristen; Madison J Ainsworth; Nino Chirico; Casper F T van der Ven; Pieter A Doevendans; Joost P G Sluijter; Jos Malda; Alain van Mil; Miguel Castilho
Journal:  Adv Healthc Mater       Date:  2019-10-11       Impact factor: 9.933

2.  Persistence of intramyocardially transplanted murine induced pluripotent stem cell-derived cardiomyocytes from different developmental stages.

Authors:  Gabriel Peinkofer; Martina Maass; Kurt Pfannkuche; Agapios Sachinidis; Stephan Baldus; Jürgen Hescheler; Tomo Saric; Marcel Halbach
Journal:  Stem Cell Res Ther       Date:  2021-01-08       Impact factor: 6.832

Review 3.  Nanotechnology in cardiac stem cell therapy: cell modulation, imaging and gene delivery.

Authors:  Elangovan Sarathkumar; Marina Victor; Jaivardhan A Menon; Kunnumpurathu Jibin; Suresh Padmini; Ramapurath S Jayasree
Journal:  RSC Adv       Date:  2021-10-26       Impact factor: 4.036

4.  In Situ Maturated Early-Stage Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Improve Cardiac Function by Enhancing Segmental Contraction in Infarcted Rats.

Authors:  Diogo Biagi; Evelyn Thais Fantozzi; Julliana Carvalho Campos-Oliveira; Marcus Vinicius Naghetini; Antonio Fernando Ribeiro; Sirlene Rodrigues; Isabella Ogusuku; Rubia Vanderlinde; Michelle Lopes Araújo Christie; Debora Bastos Mello; Antonio Carlos Campos de Carvalho; Marcos Valadares; Estela Cruvinel; Rafael Dariolli
Journal:  J Pers Med       Date:  2021-05-04

Review 5.  Strategies and Challenges to Improve Cellular Programming-Based Approaches for Heart Regeneration Therapy.

Authors:  Lin Jiang; Jialiang Liang; Wei Huang; Zhichao Wu; Christian Paul; Yigang Wang
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.